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Abstract: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease which is classically characterised by a 
variety of autoantibodies to deoxyribonucleic acid (DNA), ribonucleic acid (RNA), other nuclear and cytoplasmic 
antigens. Recently several novel autoantibodies against a variety of specific nuclear pore proteins have been described, 
including the nucleoporin p62. In this paper we evaluate anti-nucleoporin p62 antibodies by western blot analysis in 25 
systemic lupus erythematosus patients. Six patients showed antibodies directed against nucleoporin p62. Our data indicate 
that p62 antibodies could be a useful additional marker in SLE. 
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INTRODUCTION 
  Systemic lupus erythematosus is a systemic autoimmune 
disease with diverse clinical manifestations which are often 
complex and occur as a result of inflammation in target 
organs. The revised criteria of the American College of 
Rheumatology for the classification of SLE incorporate 
photosensitivity, arthritis, serositis, neurological disorders 
including seizures and psychosis, renal impairment, 
haematological disorders and impairment of the lungs, heart 
and intestine [1]. SLE is serologically defined by a variety of 
autoantibodies including anti-DNA, anti-phospholipid, anti-
Sm and other antinuclear antibodies. 
  Due to the substantial progress in elucidation of the 
structure of the nuclear membrane and pore complex, 
recently novel autoantigens localised within the nucleus and 
the nuclear envelope have been investigated in more detail. 
Enarson  et al. [2] differentiate the nuclear envelope (NE) 
into five regions, the outer nuclear membrane (ONM), an 
inter membrane space, the inner nuclear membrane (INM), 
the underlying nuclear lamina and the nuclear pore complex 
(NPC). Autoantibodies against the nuclear lamina (including 
lamins A, B and C), against integral membrane proteins of 
the INM as the lamin B receptor and lamin-associated 
polypeptides as well as autoantibodies against nuclear pore 
proteins (gp210, Nup153, Tpr, p62) have been defined in 
different autoimmune diseases [2-4]. 
  The nuclear pore complex (NPC) serves as the sole gate 
between the nucleoplasm and the cytoplasm and contains 
several different nuclear pore proteins such as nucleoporin 
p62. Nucleoporin p62 was cloned and sequenced in 1991 [5] 
and found not to be identical with the cytoplasmic RNA-
binding protein p62 which is an autoantigen in human 
hepatocellular carcinoma [6]. The amino acid sequence of 
nucleoporin p62 contains phenylalanine- and glycine- rich   
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(FG) repeat motifs, which are characteristic for nuclear pore 
proteins [5]. Nucleoporin p62 is a glycoprotein and probably 
therefore highly immunogenic [7]. Since the FG-repeat 
motifs of p62 are flexible and mobile in contrast to 
nucleoporin p58 and nucleoporin p54, which are very similar 
proteins, this flexible motif might be the reason of strong 
immunogenicity of p62 [8]. One trial described p62 as an 
oxalate-binding protein with increased expression in 
different kidney disorders [9]. 
  Nucleoporins are well described autoantigens in primary 
biliary cirrhosis where their presence might indicate a more 
severe course of the disease [10-15]. Anti-nucleoporin 
antibodies can be also found in systemic connective tissue 
diseases. For example, in four cases of Sjögren’s syndrome 
[16], four cases of systemic lupus erythematosus [9, 10] and 
one case of Sharp syndrome [17] p62 autoantibodies were 
identified. 
  In a previous study, we expressed p62 in three 
recombinant fusion proteins. Autoantibodies in primary 
biliary cirrhosis are recognizing the amino terminal fragment 
of p62 [17]. Since the aminoterminal fragment therefore 
seems to be the antigen, we used this fragment for further 
investigations in Lupus erythematosus, to evaluate, if p62 
serves as an autoantigen in this disease too. We investigated 
twenty five patients suffering from the disease. Six of the 
twenty five patients showed anti-p62 autoantibodies. 
MATERIALS AND METHODS 
Collection of Blood Samples 
  Serum blood samples of 25 patients suffering from 
systemic lupus erythematosus were collected. Prior to the 
trial the project has been approved by the ethical committee 
in Würzburg/Germany. For each patient, the trial was 
discussed in detail and the approved consent form was 
signed prior to participation. Systemic lupus erythematosus 
was diagnosed according the revised criteria of the American 
College of Rheumatology for the classification of SLE [1, 
18]. All patients were characterized by a prolonged time 
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variety of immunosuppressive drug therapies. 22 patients 
were female, 3 patients were male. Patient age ranged from 
24 years to 64 years. Median age was 41.72. To quantify the 
disease we used the SLICC/SDI damage score [19]. As 
controls we used a 24 year old and a 41 year old healthy 
woman. Both controls had no antinuclear antibodies or anti-
native DNA antibodies. 
Expression and Purification of p62 Fusion Protein 
  The amino terminal domain of p62 which contains the 
phenylalanine- and glycine-repeat (FG-repeat) domain 
(amino acid residue 1 to 329) was expressed using a set of 
non degenerate oligonucleotide primers (5’-ATGAGCGGC 
TTTAATTTTGGAGG-3’ and 5’-GGTCATGGCGGAGCT 
GGCAG-3’). Primers contained additional restriction sites 
for HindIII and XHOI. The corresponding PCR product was 
inserted between the HindIII- and XHOI restriction sites in 
pET21-b vector (Novagen, Madison, Wisconsin) containing 
a six-histidine tag. The construct was transformed into 
Escherichia coli BL21 (DE3). P62-His6 fusion protein was 
purified under denaturing conditions as described previously 
[17]. 
Gel Electrophoresis and Immunoblotting 
  P62 fusion protein was analyzed by 15% sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE; 
10g of protein/lane) and transferred to Hybond ECL 
membranes (Amersham, Braunschweig, Germany) at 50 V 
for 3 h. After a blocking step with 5% skimmed milk in 
phosphate-buffered saline (PBS; pH 7.4) for 1h at room 
temperature (RT), the Hybond sheets were incubated 
overnight at 4
0C with the control- and patient-sera (diluted 
1:500 in 5% milk). Bound antibodies were visualized with 
horseradish peroxidase-labelled goat anti-human IgG 
Table 1.  Clinical Disposition and Anti-p62 Antibodies in 25 Patients Suffering from SLE and Two Healthy Controls (C1 and C2) 
 
Pat  Age  Sex  Kidney 
Disease 
Neurologic 
Disorder 
Arthritis/
Arthralgia 
Skin 
Disease 
Haematology 
Disease 
Musculosceletal 
Disorder 
Vascular 
Disease 
ANAs  Anti 
DNS 
Anti-
p62 
SLICC/
SDI 
C1  41  f                -  -  -  0 
C2  24  f                -  -  -  0 
1  29  f    +,+  +  (+)        -  +  ++  3 
2  49  f      (+)  (+)      +  +  +  -  1 
3  29  f      (+)  +        +  +  -  1 
4  32  f      (+)          -  +  -  0 
5  30  f    (+)            -  +  -  0 
6  38  f  N (+), P(+)    (+)  (+)  (+)      +  +  -  0 
7  34  f  P(+)    (+)  (+)  (+)    (+)  +  +  -  0 
8  36  f  P(+)  +,+  (+)  (+)    (+)    +  +  -  2 
9  57  f  (+)    (+)    (+)      -  +  -  0 
10  57  m    +  (+)  (+)  (+)      +  +  -  1 
11  39  f  P(+)    (+)  +  (+)      -  +  +  1 
12  42  f      (+)    (+)      +  +  -  0 
13  36  f  N(+)    +          +  +  -  1 
14  40  f      (+)  (+)        -  +  -  0 
15  56  f  P(+)  +      (+)      +  +  -  1 
16  40  f  P(+)    +  (+)        -  +  -  1 
17  24  f  P(+)        (+)      -  +  +++  0 
18  63  f    +      (+)      +  -  -  1 
19  32  m          (+)      +  +  -  0 
20  27  f  N(+)  +  (+)  (+)  (+)      +  +  -  1 
21  35  m  N(+)    (+)  (+)        -  +  ++  0 
22  41  f          (+)      -  +  -  0 
23  46  f  N(+)    (+)    (+)    (+)  +  +  -  0 
24  64  f  N(+), P+    (+)  (+)  (+)  (+)    -  -  +++  1 
25  46  f  N+    +  (+)  (+)      +  +  ++  2 
The table shows numbered index of patients (Pat), age, gender, organ disease, p62-autoantibodies and the SLICC/SDI Damage Score for each patient. (+) symptoms without organ 
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(Jackson Immunoresearch Laboratories, West Grove, Pa.) 
diluted 1:4,000 in PBS, including 5% milk by using 
enhanced chemiluminescence (Amersham, Braunschweig, 
Germany). 
RESULTS 
  To investigate, if SLE is characterized by p62-
autoantibodies, we expressed the amino terminal fragment of 
nucleoporin p62 in E. coli. This fragment contains the FG-
repeat domains, which are not only the adhesion site for 
nuclear transport factors, but also serve as the antigenic 
epitope for p62 autoantibodies [17]. 
  We collected sera of 25 patients suffering from SLE. 
Data analysis of the patients showed, that seven patients had 
nephritis during their medical history, six patients were 
suffering from neurological disorders manifested as seizures. 
As negative controls we used two healthy women (Table 1). 
  In 6 of 25 patients (24%) a distinct band was visualised 
in the Western Blots corresponding to the binding of p62-
autoantibodies to immobilised protein (Fig. 1). Five of the 
six positive patients were female, one patient is male. The 
median age of positive patients was 39.6. Median time since 
diagnosis of disease was 11.83 years. Four of our six positive 
patients had renal disease and one of the anti-p62 positive 
patients suffered from a severe neurologic disorder 
characterised by myelitis and paraparesis of both legs. 
  To quantify severity of disease we used SLICC/SDI 
damage score [19]. Four of the six patients with anti-p62 
were already suffering from organ damage. 
DISCUSSION 
  SLE is a severe autoimmune disease characterized by 
antinuclear and anti-DNA antibodies. In this paper we 
investigated 25 SLE-patients for autoantibodies against 
nucleoporin p62. Nucleoporin p62 autoantibodies have been 
extensively studied in primary biliary cirrhosis, but have 
been rarely described in connective tissue diseases. 
  In this paper we show for the first time, that nucleoporin 
p62 serves also as an autoantigen in SLE with a frequency of 
24% of all cases tested. Of the positive cases one was male 
and five female, indicating that the presence of the 
antibodies is unrelated to gender. SLE is more frequent in 
women than in men, but seems to run a more severe course 
in male patients [20]. To characterize severity of the disease 
we used the SLICC/SD damage score, since actual disease 
activity is also dependent on current treatment. 13 of our 25 
patients were suffering from at least one site of organ 
damage. From the anti-p62 patients 4 out of 6 showed 
significant organ damage. The two patients with no organ 
damage were a male patient and the youngest patient in our 
trial, a 24 year old female. One anti-p62 positive patient had 
extraordinary severe neurological symptoms with myelitis 
and paraparesis of both legs. Four of the positive patients 
have severe kidney disease like nephritis, nephrotic 
syndrome or reduced renal function. Interestingly, it has 
been investigated, that nucleoporin p62 serves as oxalate-
binding protein and plays a role in renal stone formation [9, 
21]. Nucleoporin p62 expression and urine excretion 
increase in hyperoxaluria and vary in different kidney 
disorders. This observation might be due to increased 
expression of p62 or degradation of the cell membrane by 
oxalate-induced cell injury [9]. Oxalate, but also other cell 
toxins might induce apoptosis of cells. Nuclei undergo 
dramatic changes during apoptosis and anti nuclear pore 
complex antibodies may evolve as a result of antigenic 
presentation of proteolytic polypeptide fragments that arise 
during apoptotic cell death [22, 23]. This may allow anti-p62 
autoantibody formation in autoimmune prone patients with 
renal injuries. 
 
Fig. (1). 15% SDS PAGE of in E. coli expressed aminoterminal fragment of nucleoporin p62, transferred by Westernblot to nitrocellulose 
membrane and incubated with patient sera and control sera (C1, C2). Samples of patients 1, 11, 17, 21, 24 and 25 show positive signals, as 
indicated by arrows. 
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  In summary, we show for the first time, that p62 serves 
as an autoantigen in cases of severe systemic lupus 
erythematosus. The clinical relevance of this autoantigen has 
to be evaluated in larger cohort studies and ensured by 
further methods like ELISA technique. 
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